Evidence map›Paper›PMID 42180539›Full record

ArticleActa pharmaceutica Sinica. B2026

Targeting cancer-associated fibroblast-activated HGF/c-MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity.

Mingzhen Bai, Ping Yue, Wenkang Fu, Ruyang Zhong, Chongfei Huang, Ningzu Jiang, Long Gao, Ningning Mi, Haidong Ma, Yawen Lu and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mingzhen BaiDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Ping YueDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Wenkang FuDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Ruyang ZhongDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Chongfei HuangDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Ningzu JiangDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Long GaoDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Ningning MiDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Haidong MaDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Yawen LuDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Liang TianDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Jinyu ZhaoDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Ziang ZhangDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Yong ZhangDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Jinduo ZhangDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Yanxian RenDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Haiying YuKey Laboratory of Biological Therapy and Regenerative Medicine Transformation of Gansu Province, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Jia YaoKey Laboratory of Biological Therapy and Regenerative Medicine Transformation of Gansu Province, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Dewei LiDepartment of Hepatobiliary Pancreatic Tumor Center, Chongqing University Cancer Hospital, Chongqing 400030, China.
Yanyan LinDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.
Wenbo MengDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is a markedly desmoplastic tumor, with extrahepatic CCA (eCCA) being the most prevalent subtype. The nonspecific clinical manifestation and early metastatic potential result in a persistently poor overall prognosis. Cancer-associated fibroblasts (CAFs) are one of the major components of the tumor microenvironment implicated in tumor progression and treatment resistance. To faithfully recapitulate the eCCA microenvironment, we established a comprehensive patient-derived preclinical platform comprising CAFs, eCCA primary cells, organoids, and patient-derived xenograft (PDX) models. We found that CAFs facilitated eCCA cell growth, migration, and invasion

Indexed as

Cancer-associated fibroblastsc-METExtrahepatic cholangiocarcinomaGemcitabine resistanceHGFOrganoidsPatient-derived xenograftPrimary cells

Identifiers

PMID42180539
PMCPMC13198319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.